Financials data is unavailable for this security.
View more
Year on year Nanjing King-friend Biochemical Pharmaceutical Co Ltd had net income fall from a gain of 1.09bn to a loss of 189.45m despite a 5.89% increase in revenues from 3.71bn to 3.93bn. An increase in the cost of goods sold as a percentage of sales from 47.90% to 83.23% was a component in the falling net income despite rising revenues.
| Gross margin | 41.80% |
|---|---|
| Net profit margin | -10.85% |
| Operating margin | -14.80% |
| Return on assets | -3.92% |
|---|---|
| Return on equity | -6.45% |
| Return on investment | -5.65% |
More ▼
Cash flow in CNYView more
In 2023, Nanjing King-friend Biochemical Pharmaceutical Co Ltd increased its cash reserves by 195.43%, or 591.51m. The company earned 1.62bn from its operations for a Cash Flow Margin of 41.19%. In addition the company generated 51.20m cash from financing while 1.16bn was spent on investing.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.76 |
|---|---|
| Tangible book value per share | 3.39 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.38 |
|---|---|
| Quick ratio | 1.19 |
| Total debt/total equity | 0.4439 |
|---|---|
| Total debt/total capital | 0.3076 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -13.04% and -117.79%, respectively. Additionally, five year annualized dividend per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.56% |
|---|---|
| Div growth rate (5 year) | 13.75% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -145.86 |
More ▼
